Fig. 4.

Follow-up of belamaf-induced ocular toxicity (assessed by in vivo confocal microscopy of the cornea) in relation to symptoms and treatment management. a Peripheral cornea: specific hyperreflective deposits (HDs) are detected in basal layers at W3 before vision loss; these may constitute preclinical biomarkers for ocular toxicity. b Central cornea: belamaf-induced lesions are detected simultaneously as the vision loss and clinical signs; rechallenging with 75% of the dose contributed to decreasing the density, further keeping corneal toxicity under control. Permanent discontinuation was driven by general treatment failure